J D Amsterdam

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. doi request reprint Effectiveness and Mood Conversion Rate of Short-Term Fluoxetine Monotherapy in Patients With Rapid Cycling Bipolar II Depression Versus Patients With Nonrapid Cycling Bipolar II Depression
    Jay D Amsterdam
    From the Depression Research Unit, Department of Psychiatry and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA
    J Clin Psychopharmacol 33:420-4. 2013
  2. pmc Efficacy and mood conversion rate during long-term fluoxetine v. lithium monotherapy in rapid- and non-rapid-cycling bipolar II disorder
    Jay D Amsterdam
    Depression Research Unit, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Br J Psychiatry 202:301-6. 2013
  3. doi request reprint Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, United States
    J Affect Disord 112:219-30. 2009
  4. ncbi request reprint A preliminary study of dopamine transporter binding in bipolar and unipolar depressed patients and healthy controls
    Jay D Amsterdam
    Department of Psychiatry, The Depression Research Unit, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Neuropsychobiology 55:167-70. 2007
  5. ncbi request reprint Safety and efficacy of s-citalopram in patients with co-morbid major depression and diabetes mellitus
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 3309, USA
    Neuropsychobiology 54:208-14. 2006
  6. doi request reprint Venlafaxine monotherapy in bipolar type II depressed patients unresponsive to prior lithium monotherapy
    J D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Acta Psychiatr Scand 121:201-8. 2010
  7. ncbi request reprint Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA
    J Clin Psychopharmacol 26:579-86. 2006
  8. ncbi request reprint MAOI efficacy and safety in advanced stage treatment-resistant depression--a retrospective study
    Jay D Amsterdam
    Depression Research Unit, University Science Center 3rd Floor, 3535 Market Street, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 3309, United States
    J Affect Disord 89:183-8. 2005
  9. ncbi request reprint Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry bCenter for Clinical Epidemiology and Bio statistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Int Clin Psychopharmacol 20:257-64. 2005
  10. ncbi request reprint Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, United States
    Prog Neuropsychopharmacol Biol Psychiatry 32:100-6. 2008

Detail Information

Publications52

  1. doi request reprint Effectiveness and Mood Conversion Rate of Short-Term Fluoxetine Monotherapy in Patients With Rapid Cycling Bipolar II Depression Versus Patients With Nonrapid Cycling Bipolar II Depression
    Jay D Amsterdam
    From the Depression Research Unit, Department of Psychiatry and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA
    J Clin Psychopharmacol 33:420-4. 2013
    ..We hypothesized that there would be reduced antidepressant effectiveness and a greater mood conversion rate over time in patients with rapid cycling...
  2. pmc Efficacy and mood conversion rate during long-term fluoxetine v. lithium monotherapy in rapid- and non-rapid-cycling bipolar II disorder
    Jay D Amsterdam
    Depression Research Unit, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Br J Psychiatry 202:301-6. 2013
    ..Controversy exists over antidepressant use in rapid-cycling bipolar disorder...
  3. doi request reprint Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, United States
    J Affect Disord 112:219-30. 2009
    ..We hypothesized that lithium would have superior efficacy to venlafaxine, with fewer syndromal and sub-syndromal hypomanic and mixed mood conversions in the rapid cycling BP II MDE patients...
  4. ncbi request reprint A preliminary study of dopamine transporter binding in bipolar and unipolar depressed patients and healthy controls
    Jay D Amsterdam
    Department of Psychiatry, The Depression Research Unit, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Neuropsychobiology 55:167-70. 2007
    ..We hypothesized that DAT levels might be higher in bipolar versus unipolar patients...
  5. ncbi request reprint Safety and efficacy of s-citalopram in patients with co-morbid major depression and diabetes mellitus
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 3309, USA
    Neuropsychobiology 54:208-14. 2006
    ..We examined the safety and efficacy of s-citalopram therapy in patients with co-morbid depression and diabetes, and its ability to improve glycemic control...
  6. doi request reprint Venlafaxine monotherapy in bipolar type II depressed patients unresponsive to prior lithium monotherapy
    J D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Acta Psychiatr Scand 121:201-8. 2010
    ..We hypothesized that venlafaxine would be superior to lithium with a low hypomanic conversion rate...
  7. ncbi request reprint Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA
    J Clin Psychopharmacol 26:579-86. 2006
    ..In conclusion, STS was well tolerated and efficacious in maintaining a sustained response in MDD patients. The results of this study suggest that STS may be suitable in the long-term treatment of MDD...
  8. ncbi request reprint MAOI efficacy and safety in advanced stage treatment-resistant depression--a retrospective study
    Jay D Amsterdam
    Depression Research Unit, University Science Center 3rd Floor, 3535 Market Street, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 3309, United States
    J Affect Disord 89:183-8. 2005
    ....
  9. ncbi request reprint Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry bCenter for Clinical Epidemiology and Bio statistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Int Clin Psychopharmacol 20:257-64. 2005
    ..Larger-scale studies are needed to confirm these findings...
  10. ncbi request reprint Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, United States
    Prog Neuropsychopharmacol Biol Psychiatry 32:100-6. 2008
    ..Treatment of CFS has generally been disappointing. We hypothesized that s-citalopram therapy may improve the symptoms of both disorders in CFS patients with co-morbid depression...
  11. doi request reprint Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study
    Jay D Amsterdam
    Department of Psychiatry, Depression Research Unit, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 3309, USA
    J Clin Psychopharmacol 28:171-81. 2008
    ..We hypothesized that initial AD monotherapy would be superior to MS monotherapy for BP II MDE with a low hypomanic switch rate...
  12. doi request reprint Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 3309, United States
    J Affect Disord 115:234-40. 2009
    ..We hypothesized that a greater number of prior antidepressant exposures would result in a reduced response to venlafaxine, but not lithium, therapy...
  13. doi request reprint Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 3309, USA
    Neuropsychobiology 59:227-33. 2009
    ..The aim of this post hoc analysis was to examine whether tachyphylaxis occurs after repeated courses of antidepressant drug therapy...
  14. pmc A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder
    Jay D Amsterdam
    Depression Research Unit, University Science Center, 3rd Floor, 3535 Market St, Philadelphia, PA 19104 3309, USA
    J Clin Psychopharmacol 29:378-82. 2009
    ..We hypothesized that chamomile would be superior to placebo in reducing GAD symptoms with a comparable tolerability profile...
  15. pmc Randomized, double-blind, placebo-controlled trial of Cimicifuga racemosa (black cohosh) in women with anxiety disorder due to menopause
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 3309, USA
    J Clin Psychopharmacol 29:478-83. 2009
    ..We hypothesized that black cohosh would be superior to placebo in reducing anxiety symptoms of menopause, with a comparable tolerability profile to placebo...
  16. pmc Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Am J Psychiatry 167:792-800. 2010
    ..The authors hypothesized that fluoxetine monotherapy would be superior to lithium monotherapy with a similar hypomanic mood conversion rate...
  17. pmc Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    J Clin Psychopharmacol 30:306-11. 2010
    ..We hypothesized that there would be a statistically significant reduction in depressive symptoms without a clinically meaningful increase in mood conversion symptoms...
  18. ncbi request reprint Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, United States
    J Affect Disord 87:121-30. 2005
    ..This preliminary, placebo-controlled study examines the relative rates of treatment-emergent manic symptoms during fluoxetine monotherapy, olanzapine monotherapy, and combined fluoxetine plus olanzapine therapy of BP I and BP II MDE...
  19. ncbi request reprint Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trial
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, University Science Center, 3535 Market Street, 3rd Floor, Philadelphia, PA 19104, USA
    J Psychiatr Res 38:259-65. 2004
    ..Gepirone-IR was significantly more effective than placebo for relapse prevention and demonstrated acceptable tolerability in outpatient responders with MDD...
  20. ncbi request reprint Antidepressant monotherapy for bipolar type II major depression
    Jay D Amsterdam
    Department of Psychiatry, Depression Research Unit, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Bipolar Disord 5:388-95. 2003
    ..Recent studies have provided evidence that antidepressant monotherapy may be an effective initial and long-term treatment for BP II major depression with a low manic-switch rate...
  21. ncbi request reprint Greater availability of brain dopamine transporters in major depression shown by [99m Tc]TRODAT-1 SPECT imaging
    David J Brunswick
    Depression Research Unit, Department of Radiology, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Am J Psychiatry 160:1836-41. 2003
    ..The present study was an examination of the availability of brain dopamine transporter sites in patients with major depression and in healthy comparison subjects...
  22. ncbi request reprint A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, USA
    J Clin Psychiatry 64:208-14. 2003
    ..This novel transdermal system provides targeted MAO inhibition without clinically significant increases in sensitivity to dietary tyramine. We investigated the safety and efficacy of STS in patients with major depressive disorder...
  23. ncbi request reprint A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A--a putative, new antidepressant
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Prog Neuropsychopharmacol Biol Psychiatry 26:1333-8. 2002
    ..YKP10A is a novel, new antidepressant that may affect dopamine neurotransmission. We present results from the first Phase II clinical trial of YKP10A antidepressant activity in patients with major depression...
  24. ncbi request reprint Site variability in treatment outcome in antidepressant trials
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, 3rd Floor, University Science Center, University of Pennsylvania School of Medicine, 3535 Market Street, Philadelphia, PA 19104, USA
    Prog Neuropsychopharmacol Biol Psychiatry 26:989-93. 2002
    ..As part of a five-site, long-term, double-blind, placebo-controlled, relapse prevention trial with fluoxetine in major depression, the authors examined site-specific variability in outcome ratings...
  25. ncbi request reprint Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression - low manic switch rate
    Jay D Amsterdam
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Bipolar Disord 6:75-81. 2004
    ..This recommendation is the result of concern over antidepressant-induced manic switch episodes. However, recent evidence suggests that the manic switch rate may be low in BP II MDE during SSRI therapy...
  26. ncbi request reprint Prevention of relapse following cognitive therapy vs medications in moderate to severe depression
    Steven D Hollon
    Department of Psychology, Vanderbilt University, 306 Wilson Hall Nashville, TN 37203, USA
    Arch Gen Psychiatry 62:417-22. 2005
    ..Antidepressant medication prevents the return of depressive symptoms, but only as long as treatment is continued...
  27. ncbi request reprint Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression
    P J McGrath
    Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, USA
    J Clin Psychiatry 61:518-24. 2000
    ..The goal was to examine predictors of relapse during continuation/maintenance treatment of major depression that had remitted following 12 to 14 weeks of fluoxetine therapy...
  28. pmc Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapy
    Sunil S Bhar
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Affect Disord 110:161-6. 2008
    ..The authors examined the patterns of improvement in cognitive and vegetative symptoms of major depression in individuals treated with cognitive therapy (CT) or pharmacotherapy (PT)...
  29. ncbi request reprint Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study
    David L Dunner
    Center for Anxiety and Depression and the Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, USA
    J Clin Psychiatry 68:1071-7. 2007
    ..To evaluate the efficacy and tolerability of adjunctive ziprasidone in subjects with treatment-resistant major depressive disorder (DSM-IV criteria) without psychotic features...
  30. ncbi request reprint The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability
    Donald S Robinson
    Worldwide Drug Development, 102 East Avenue, Burlington, VT 05401, United States
    J Affect Disord 105:15-23. 2008
    ..Monoamine oxidase inhibitors (MAOIs) are highly efficacious antidepressants, but safety concerns have limited their broad use...
  31. ncbi request reprint Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients
    J Alexander Bodkin
    McLean Hospital, 115 Mill St Belmont, MA 02478, USA
    Am J Psychiatry 159:1869-75. 2002
    ..The authors investigated the efficacy and safety of transdermal selegiline in adult outpatients with major depressive disorder...
  32. ncbi request reprint Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale
    Anita H Clayton
    Department of Psychiatry and Neurobehavioral Sciences, University of Virginia Health System, Charlottesville, VA 22908, USA
    J Clin Psychiatry 68:1860-6. 2007
    ..The objective of this study was to examine the impact of STS 6 mg/24 hours on various domains of sexual function in patients with major depressive disorder (MDD), using a patient-rated questionnaire...
  33. ncbi request reprint Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study
    David Michelson
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, Ind, USA
    J Clin Psychiatry 68:582-7. 2007
    ..Addition of a noradrenergic intervention in patients poorly or partially responsive to SSRIs may improve outcomes, but few well-controlled studies testing this hypothesis have been reported...
  34. ncbi request reprint Cognitive therapy vs medications in the treatment of moderate to severe depression
    Robert J Derubeis
    Department of Psychology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Arch Gen Psychiatry 62:409-16. 2005
    ..There is substantial evidence that antidepressant medications treat moderate to severe depression effectively, but there is less data on cognitive therapy's effects in this population...
  35. ncbi request reprint Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment
    David J Brunswick
    The Depression Research Unit, University of Pennsylvania Medical Center, University Science Center, 8th Floor, 3600 Market Street, Philadelphia, PA 19104, USA
    J Affect Disord 68:243-9. 2002
    ..The purpose of this study was to investigate the relationship between steady-state plasma drug concentrations and outcome during relapse-prevention therapy with fluoxetine...
  36. pmc Antidepressant drug effects and depression severity: a patient-level meta-analysis
    Jay C Fournier
    Department of Psychology, University of Pennsylvania, 3720 Walnut St, Philadelphia, PA 19104, USA
    JAMA 303:47-53. 2010
    ....
  37. ncbi request reprint PET brain imaging with [11C](+)McN5652 shows increased serotonin transporter availability in major depression
    Martin Reivich
    Cerebrovascular Research Center, Department of Neurology, University of Pennsylvania School of Medicine, Room 415 Stemmler Hall, Philadelphia, PA 19104 6063, USA
    J Affect Disord 82:321-7. 2004
    ....
  38. ncbi request reprint 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study
    Andrew B Newberg
    Division of Nuclear Medicine, Department of Radiology, University of Pennsylvania School of Medicine, 3400 Spruce Street, Philadelphia, PA 19104, USA
    J Nucl Med 46:973-7. 2005
    ..We hypothesized that SERT binding activity may be altered in patients with MDD. This study compared SERT binding in patients with MDD with that in healthy controls...
  39. pmc Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression
    Jay C Fournier
    Department of Psychology, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Consult Clin Psychol 77:775-87. 2009
    ..The 3 prognostic variables identify subgroups that might benefit from alternative treatment strategies; the 3 prescriptive variables identify groups who appear to respond particularly well to cognitive therapy...
  40. ncbi request reprint A prospective trial of sertraline for chronic subjective dizziness
    Jeffrey P Staab
    Department of Psychiatry, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA
    Laryngoscope 114:1637-41. 2004
    ....
  41. ncbi request reprint Mood disorders in women from adolescence to late life: an overview
    Rhonda C Boyd
    Department of Psychiatry, University of Pennsylvania School of Medicine and Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Clin Obstet Gynecol 47:515-26. 2004
  42. ncbi request reprint The relation of patients' treatment preferences to outcome in a randomized clinical trial
    Yan Leykin
    Department of Psychology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Behav Ther 38:209-17. 2007
    ..These results do not provide support for the claim that the external validity of randomized controlled trials suffers from this aspect of the randomization procedure...
  43. ncbi request reprint Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression
    Yan Leykin
    Department of Psychology, University of Pennsylvania, Philadelphia, PA 19104 6196, USA
    J Consult Clin Psychol 75:267-76. 2007
    ..If these findings are replicated in methodologically rigorous studies of paroxetine and other antidepressants, CT should be recommended, in preference to AD, for patients with multiple prior AD exposures...
  44. ncbi request reprint Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications
    Cristina Cusin
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 68:52-7. 2007
    ..While patterns of response have been examined as possible predictors of outcome, the clinical correlates and implications of early worsening per se have not been investigated...
  45. ncbi request reprint Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depression
    Mady Hornig-Rohan
    Depression Research Unit, University Science Center, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    Prog Neuropsychopharmacol Biol Psychiatry 26:585-9. 2002
    ..The present study examined treatment outcome with antidepressants and/or stimulants in adults with ADD who initially presented with a diagnosis of MDD...
  46. pmc Antidepressant medications v. cognitive therapy in people with depression with or without personality disorder
    Jay C Fournier
    Department of Psychology, University of Pennsylvania, Philadelphia, PA 19104 6196, USA
    Br J Psychiatry 192:124-9. 2008
    ..There is conflicting evidence about comorbid personality pathology in depression treatments...
  47. pmc The effect of post-injury depression on return to pre-injury function: a prospective cohort study
    T S Richmond
    University of Pennsylvania, Philadelphia, 19104, USA
    Psychol Med 39:1709-20. 2009
    ..Little is known about the effect of psychiatric co-morbid disorders that emerge after minor injury on functional recovery. This study examined the effect of post-injury depression on return to pre-injury levels of function...
  48. ncbi request reprint Pindolol does not augment cortisol and prolactin responses to paroxetine in healthy subjects
    David J Brunswick
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Prog Neuropsychopharmacol Biol Psychiatry 28:477-80. 2004
    ....
  49. ncbi request reprint Acute mood and thyroid stimulating hormone effects of transcranial magnetic stimulation in major depression
    M P Szuba
    University of Pennsylvania, Department of Psychiatry, Philadelphia, Pennsylvania 19104, USA
    Biol Psychiatry 50:22-7. 2001
    ..CONCLUSIONS: This blinded, placebo-controlled trial documents that individual rTMS sessions can acutely elevate mood and stimulate TSH release in patients experiencing major depressive episodes...
  50. ncbi request reprint Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression
    Martin P Szuba
    Depression Research Unit, Department of Psychiatry, University of Pennsylvania School of Medicine, University Science Center, 3535 Market Street, Philadelphia, PA 19104, USA
    J Clin Psychopharmacol 25:325-30. 2005
    ..We hypothesized that nocturnal administration of TRH, when the circadian sensitivity of the TRH receptor is at its peak, may result in a more robust antidepressant effect...
  51. ncbi request reprint Neuroendocrine aspects of chronic fatigue syndrome
    Dimitris A Papanicolaou
    Department of Medicine Endocrinology, Emory University, Atlanta, GA, USA
    Neuroimmunomodulation 11:65-74. 2004
    ..This paper represents the consensus of the panel of experts who participated in this meeting...
  52. ncbi request reprint Immunologic aspects of chronic fatigue syndrome. Report on a Research Symposium convened by The CFIDS Association of America and co-sponsored by the US Centers for Disease Control and Prevention and the National Institutes of Health
    Timothy R Gerrity
    Worcester Polytechnic Institute, Worcester, Mass, USA
    Neuroimmunomodulation 11:351-7. 2004
    ..It has become clear that CFS cannot be understood based on single measurements of immune, endocrine, cardiovascular, or autonomic nervous system dysfunction. This panel encourages a new emphasis on multidisciplinary research into CFS...

Research Grants17

  1. 1/2-Prevention of Relapse & Recurrence of Bipolar Depression
    Jay D Amsterdam; Fiscal Year: 2010
    ..Results from this study may also inform new research hypotheses for future trials in BP I disorder. ..
  2. Treatment of Bipolar Type II Major Depression
    Jay D Amsterdam; Fiscal Year: 2010
    ..If our hypotheses are correct, we believe that these results may have an important public health impact on the current practice guidelines for treating BP II MDE. ..
  3. Long-Term Chamomile Therapy of Generalized Anxiety Disorder
    Jay Amsterdam; Fiscal Year: 2009
    ..It also found chamomile to be well tolerated. The present application will extend these promising results by studying the long-term benefit of chamomile in preventing relapse of anxiety. ..
  4. 1/2-Prevention of Relapse & Recurrence of Bipolar Depression
    Jay Amsterdam; Fiscal Year: 2009
    ..Results from this study may also inform new research hypotheses for future trials in BP I disorder. ..
  5. Treatment of Bipolar Type II Major Depression
    Jay Amsterdam; Fiscal Year: 2007
    ..If our hypotheses are correct, we believe that these results may have an important public health impact on the current practice guidelines for treating BP II MDE. ..
  6. SPECT Brain Imaging as a Biomarker of Major Depression
    Jay Amsterdam; Fiscal Year: 2007
    ..We will compare these results to measurements of striatal DAT levels in 22 non-depressed, healthy subjects studied under similar conditions with [99mTc]TRODAT-1 SPECT on two separate occasions 8 weeks apart. ..
  7. Chamomile therapy for generalized anxiety disorder
    Jay Amsterdam; Fiscal Year: 2006
    ....
  8. Black cohosh therapy for menopause-related anxiety
    Jay Amsterdam; Fiscal Year: 2006
    ..We hypothesize that Black Cohosh will result in superior QOL measures compared to placebo. ..
  9. RELAPSE PREVENTION OF BIPOLAR TYPE-II DISORDER
    Jay Amsterdam; Fiscal Year: 2005
    ..We believe that our study has the potential to have a significant impact upon current clinical practice in the appropriate management of bipolar depressed patients; an extremely important public-health matter. ..
  10. Long-Term Chamomile Therapy of Generalized Anxiety Disorder
    Jay D Amsterdam; Fiscal Year: 2010
    ..It also found chamomile to be well tolerated. The present application will extend these promising results by studying the long-term benefit of chamomile in preventing relapse of anxiety. ..